Targovax to present at upcoming conferences
(Thomson Reuters ONE) -
Oslo, Norway, 6 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE:
TRVX), a clinical stage company focused on developing immuno-oncology therapies
to target, primarily, treatment-resistant solid tumors, announces that members
of its senior management will present at the following life sciences and
investor conferences:
10th European Life Science CEO Forum (hosted by Sachs Associates)
Date: 7 March 2017
Venue: Hilton Zurich Airport Hotel, Zurich, Switzerland
Panel discussion time: 11:10 CET - Advances in Immuno-Oncology Therapeutics
Panel
- Magnus Jäderberg (CMO)
Presentation time: 12:25 CET
- Øystein Soug (CEO)
Redeye - Fight Cancer Seminar
Date: 10 March 2017
Venue: Redeye, Stockholm, Sweden
Presentation time: 10:50 CET
Participants: Øystein Soug (CEO)
11th Annual BIO-Equity Spring 2017 Conference
Date: 20-22 March 2017
Venue: CCIB Convention Centre in Barcelona, Spain
Participants: Øystein Soug (CEO) and Peter Skorpil (VP Business Development)
The presentations will be available to download at www.targovax.com following
these events.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli(at)targovax.com
Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: stiff(at)crux.no
Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax(at)fticonsulting.com
About Targovax
Arming the patient's immune system to fight cancer
Targovax is a clinical stage company focused on developing and commercializing
novel immuno-oncology therapies to target, primarily, treatment-resistant solid
tumors. Immuno-oncology is currently one of the fastest growing therapeutic
fields in medicine.
The Company's development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses, an emerging class of
biological therapy. ONCOS exclusively uses an adenovirus that has been
engineered to be a tumor-targeted immune activator. The platform has the
potential to generate therapies with superior efficacy and safety compared to
the first approved oncolytic virus therapy, Imlygic®, launched by Amgen. We
continue to expect key proof of concept data for this platform in 2017 from a
clinical study of lead program ONCOS-102 in patients with refractory malignant
melanoma.
The second platform, TG-Peptides (TGP), solely targets tumors that express
mutated forms of the RAS protein. Mutations to this protein are common in many
cancers and are known to drive aggressive disease progression and treatment
resistance. There is a high unmet medical need for therapies that are effective
against tumors that express these mutations. The TGP platform's therapeutic
potential stems from its ability to enable a patient's immune system to identify
and then destroy tumors bearing any RAS mutations. In early 2017, key proof of
concept data for the TGP platform from a clinical study of TG01 in resected
pancreatic cancer patients showed encouraging overall survival and will
determine plans for the future clinical development of this platform.
Targovax's development pipeline has three novel therapeutic candidates in
clinical development covering six indications. Already promising safety and
tolerability data and early signs of clinical response have been demonstrated.
Both platforms are protected by an extensive portfolio of IP and know-how and
have the potential to yield multiple product candidates in a cost-effective
manner. We have a number in early stages of development in addition to the three
outlined above.
In July, 2016 the Company listed its shares on Oslo Axess.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.03.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 528170
Anzahl Zeichen: 4888
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 206 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax to present at upcoming conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
